Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
AVT06 (aflibercept low dose biosimilar) / Cipla, Alvotech, Stada, Fuji Pharma, Teva, Polifarma, Advanz Pharma
ALVOEYE, NCT05155293 / 2021-003651-42: Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea	Active, not recruiting	3	413	Europe, Japan, RoW	AVT06 (proposed aflibercept biosimilar), Eylea® (Aflibercept)	Alvotech Swiss AG	Neovascular (Wet) AMD	11/23	10/24
ALVOEYE-D, NCT05986786: Clinical Study to Evaluate the Handling and Safety of AVT06 PFS in Subjects With Chorioretinal Vascular Disease	Active, not recruiting	3	35	RoW	Patients will receive 1 IVT injection of AVT06 PFS depending on their chorioretinal vascular disease schedule	Alvotech Swiss AG	Chorioretinal Vascular Disease	04/24	04/25